← IndicationsOpen filtered programs
Landscape
Tinnitus
Tinnitus has 60 tracked records across 20 named organizations, including 2 strong-evidence records and 14 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.
60
Pipeline Records
strong evidence + caveats + candidates
2
Strong Evidence
58 checked records with caveats
14
Active Programs
currently active
0
Marketed / Approved
commercial or approved
20
Organizations
companies, sponsors, and institutions
Competitive Density
78/100
organization breadth + program volume
Pipeline Velocity
24/100
active and late-stage share
Evidence Coverage
3/100
share strong evidence
Completion Signal
27/100
late-stage, approved, or marketed
Attrition Rate
13/100
share discontinued
Concentration
62/100
top-organization share
Programs by Stage
Early Phase 12 · 3%
Phase 19 · 15%
Phase 219 · 32%
Phase 2/32 · 3%
Phase 38 · 13%
Phase 48 · 13%
Interventional/NA3 · 5%
Not applicable9 · 15%
Trial / Program Status
Active14 · 23%
Completed31 · 52%
Discontinued8 · 13%
Paused1 · 2%
Unknown6 · 10%
Modality Breakdown
Small Molecule44 · 73%
Steroid/Anti-inflammatory9 · 15%
Biologic2 · 3%
Biologic/Nutraceutical1 · 2%
Cell Therapy1 · 2%
Regenerative Medicine1 · 2%
Small Molecule/Inhaled Gas1 · 2%
Small Molecule/Traditional Medicine1 · 2%
Program Types
Therapeutic60 · 100%
Top Organizations
Institution-led study37 · 62%
Investigator-led study4 · 7%
Otonomy2 · 3%
Altamira Therapeutics1 · 2%
Applied Biology, Inc.1 · 2%
AudioCure Pharma1 · 2%
Autifony Therapeutics Limited1 · 2%
Bayer AG1 · 2%
Population Tags
adult58 · 97%
tinnitus54 · 90%
sensorineural10 · 17%
noise-induced9 · 15%
sudden7 · 12%
repurposed-drug6 · 10%
older-adult4 · 7%
study-level4 · 7%
unilateral4 · 7%
age-related3 · 5%
Strong-Evidence Programs
2 recordsChecked Records With Caveats
58 recordsOTO-313 by Otonomy
Company: Otonomy · Phase 2 · Discontinued
Small MoleculePhase 2Discontinued96% confidence
AM-101 by Auris Medical and Altamira
Company: Altamira Therapeutics · Phase 3 · Discontinued
Small MoleculePhase 3Discontinued93% confidence
NHPN-1010
Company: Otologic Pharmaceutics · Phase 1 · Completed
Small MoleculePhase 1Completed89% confidence
OTO-104 (dexamethasone) by Otonomy
Company: Otonomy · Phase 3 · Discontinued
Steroid/Anti-inflammatoryPhase 3Discontinued90% confidence
Isosorbide Oral Solution by Lunan Better PharmaceuticalStatus caveat
Company: Lunan Better Pharmaceutical Co., Ltd. · Phase 2/3 · Active
Small MoleculePhase 2/3Active88% confidence
Neramexane by MerzStatus caveat
Company: Merz Pharmaceuticals GmbH · Phase 3 · Completed
Small MoleculePhase 3Completed86% confidence
Vestipitant tinnitus study by GSKStatus caveat
Company: GlaxoSmithKline · Phase 2 · Completed
Small MoleculePhase 2Completed90% confidence
São Paulo topical lidocaine tinnitus studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Small MoleculeNot applicableCompleted88% confidence
Deanxit tinnitus add-on studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 4 · Completed
Small MoleculePhase 4Completed87% confidence
Nitrous oxide tinnitus crossover trialStatus caveat
Sponsor / Institution: Institution-led study · Phase 4 · Completed
Small Molecule/Inhaled GasPhase 4Completed87% confidence
Fudan oral prednisone acute tinnitus studiesStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Steroid/Anti-inflammatoryNot applicableCompleted87% confidence
Xijing Wuling Capsule chronic tinnitus studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Small Molecule/Traditional MedicineNot applicableCompleted87% confidence
AUT00063 by Autifony TherapeuticsStatus caveat
Company: Autifony Therapeutics Limited · Phase 2 · Completed
Small MoleculePhase 2Completed86% confidence
University of Michigan Soundbites micronutrient NIHL prevention studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Completed
Small MoleculePhase 2Completed86% confidence
Selurampanel (BGG492) by NovartisStatus caveat
Company: Novartis Pharmaceuticals · Phase 2 · Completed
Small MoleculePhase 2Completed86% confidence
Gabapentin tinnitus study clusterStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Completed
Small MoleculePhase 2Completed86% confidence
Gabapentin tinnitus trialStatus caveat
Sponsor / Institution: Institution-led study · Phase 2/3 · Discontinued
Small MoleculePhase 2/3Discontinued86% confidence
Ginkgo biloba tinnitus study clusterStatus caveat
Sponsor / Institution: Institution-led study cluster · Not applicable · Completed
Small MoleculeNot applicableCompleted86% confidence
Leiden PREDMEN intratympanic methylprednisolone Meniere disease studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 3 · Active
Steroid/Anti-inflammatoryPhase 3Active86% confidence
Syntocinon oxytocin nasal-spray tinnitus studyStatus caveat
Sponsor / Institution: Investigator-led study · Not applicable · Completed
Small MoleculeNot applicableCompleted86% confidence